Czech quality for better health worldwide
VUAB Pharma a.s. is a leading Czech pharmaceutical company with a rich tradition dating back to 1949. For more than 75 years, we have been focusing on the production and distribution of medicines and pharmaceutical active ingredients with emphasis on quality, innovation and environmental responsibility.
Tradition in quality, innovation for the future.
Innovations built on the solid foundations of tradition and quality.
>%
Export to abroad
We are one of the three largest global producers of nystatin API. Our hospital injections, which are widely used in surgeries around the world.
mil. EUR
Turnover in 2023
mil. EUR
Turnover in 2022
Our diverse product range includes hospital injections, nystatin API, oncological API and green biosynthesis of pharmaceutical enzymes.
employees
The force that contributes to growth and stability
The excellent reputation that VUAB Pharma a.s. has earned in the pharmaceutical industry is based on its tradition, experience and responsible approach to employees
What distinguishes us
- Research, development, production, trade and transition from research to production
- 75 years of experience in the field of pharmacy
- Certification GMP and FDA
- Mental ownership – patents, trademarks
- Production processes
- Green synthesis of enzymes and nucleosides
Our vision
We want to be a leading pharmaceutical company that produces selected generic medicines and active pharmaceutical ingredients with high added value for specialized markets.
Our mission
Quality, expertise, sustainability and innovation are key to the success of VUAB Pharma a.s.
State-of-the-art technology at each stage of production
Responsibility to nature, dedication to innovations
- SAFICHEM GROUP is a leading industrial group focused on selected business areas with high added value, which include comprehensive engineering, production of pharmaceuticals, renewable energy and asset management.
- The management of SAFICHEM GROUP AG is headquartered in Zurich, Switzerland. The companies of the group operate on an international level and employ a total of 450, predominantly highly qualified employees.
- Research and development of promising new technologies and products are an integral part of the group. Each business area places full priority on environmental safety and ESG in its entirety.
- Even though the business areas of the group are interconnected, they cover a wide range of sectors. This diversification leads to a strong financial platform that strengthens the sustainability of the group and supports future growth.